CNBC put the number on it: $106 billion. That is total biotech M&A in 2026 through early June across 201 deals, putting the year on pace to be the strongest dealmaking year since before the pandemic. The average deal value spiked to $527 million, up from $365 million in 2025. CNBC noted that AstraZeneca, Pfizer, and Bristol Myers Squibb have each allocated more than $16 billion to collaborations with Chinese drugmakers since the start of 2025. EY partner Jessica Kumar described companies focused on “buying products that are going to be commercial soon, alongside investing in earlier-stage assets to get access to new technologies.” Forbion’s Luneborg said “clearly the interest in buying assets out of China is not fading” despite regulatory uncertainty. The drivers we have tracked all year are now consensus: patent cliff urgency, deep cash reserves, attractive biotech valuations, and a historically productive China licensing pipeline. Separately, the U.S. Supreme Court sided with Hikma on Vascepa patents in a ruling with implications for patent enforcement across pharma. Lilly reached a Medicare deal that restores Zepbound coverage and includes Foundayo. And Gilead cut 87% of Arcellx’s workforce following its $7.8 billion acquisition.
Top Story: $106B in Biotech M&A — The Numbers Behind a Historic Year
What Happened: CNBC reported on June 4 that biotech dealmaking has reached $106 billion in 2026 through early June, on pace for the best M&A year since before COVID.
The Data Points
The CNBC report, citing PitchBook data, highlighted several dimensions of the dealmaking surge:
201 deals have been completed or announced through early June. The average deal value has risen to $527 million, up from $365 million in 2025—a 44% increase that reflects both larger individual transactions and a shift toward later-stage, higher-value assets.
AstraZeneca, Pfizer, and Bristol Myers Squibb have each allocated more than $16 billion to collaborations with Chinese drugmakers since the start of 2025. The China licensing pipeline—which we have tracked since the BMS/Hengrui deal on May 12 through Pfizer/Innovent ($10.5 billion) and Lilly/Haisco ($3 billion+) last week—is now recognized by CNBC as a structural driver of industry dealmaking, not a one-off phenomenon.
What the Industry Is Saying
EY partner Jessica Kumar described a market where companies are focused on “buying products that are going to be commercial soon, alongside investing in earlier-stage assets to get access to new technologies.” That dual-track approach is visible in the 2026 deal data: Lilly’s Centessa acquisition ($7.8 billion, late-stage narcolepsy) sits alongside its Engage Biologics deal (undisclosed, preclinical non-viral delivery). The industry is buying both near-term revenue and long-term platform optionality simultaneously.
Forbion’s Sander Slootweg described a market where companies are “buying stuff like it’s going out of fashion.” The characterization is vivid but not quite right—the buying is strategic, not impulsive. The deals are diversified across modalities (ADCs, bispecifics, cell therapy, gene editing, vaccines, GLP-1) and therapeutic areas (oncology, metabolic disease, neuroscience, immunology, infectious disease). What makes 2026 exceptional is not that companies are buying recklessly but that they are buying at unprecedented volume and breadth because the patent cliff creates genuine urgency.
Forbion’s Luneborg on the China pipeline: “clearly the interest in buying assets out of China is not fading” despite the COINS Act push and regulatory uncertainty. The clinical data are overriding the geopolitical concerns. Merck’s sac-TMT produced two Phase 3 wins. Akeso’s ivonescimab made the ASCO plenary. Hengrui presented 90-plus studies at ASCO. When the data are this strong, the deals follow regardless of the political environment.
Putting $106B in Context
The $106 billion figure aligns with but slightly exceeds the metrics we have reported throughout the year. Reuters reported $84 billion in Q1 alone (Dealogic data). BioWorld tracked $93 billion through April. J.P. Morgan cataloged $40.2 billion in pharma and $26.6 billion in medtech through Q1. The different data sources use different methodologies (some include licensing milestones, others count only upfront payments, some include medtech while others focus on biopharma). Regardless of the exact count, 2026 is a historic year that is reshaping the composition of every major pharmaceutical company’s pipeline.
This is not a bubble. The deals are backed by clinical data (Phase 3 readouts driving acquisition premiums), driven by genuine commercial need (patent cliff revenue replacement), and executed by companies with the balance sheets to support them. The question is not whether the pace is sustainable—it is whether the organizational bandwidth to integrate this many transactions simultaneously exists across the industry.
Supreme Court Sides with Hikma on Vascepa Patents
What Happened: The U.S. Supreme Court ruled that Hikma Pharmaceuticals’ generic version of Amarin’s Vascepa (icosapent ethyl) does not infringe patents held by the Irish company.
Why This Matters Beyond Vascepa
The ruling opens the door for generic competition in the cardiovascular fish oil market. But its significance extends well beyond a single product. The Court’s decision addresses how method-of-treatment patents are evaluated in generic challenges—a patent category that pharmaceutical companies frequently use to extend branded drug exclusivity beyond the expiration of the underlying composition-of-matter patent.
Method-of-treatment patents claim not the drug molecule itself but the method of using it for a specific clinical purpose. Amarin’s patent estate attempted to block generic icosapent ethyl by claiming the method of use—reducing cardiovascular risk in patients with elevated triglycerides—was separately patented. The Court disagreed, ruling that Hikma’s generic does not infringe.
The implication for the broader industry is significant. Many pharmaceutical companies rely on method-of-treatment patents as part of their exclusivity strategy. The patents are typically layered on top of composition-of-matter patents to create what the industry calls a “patent thicket”—a dense network of overlapping patent claims designed to deter generic challengers. The SCOTUS ruling suggests that method-of-treatment patents may be harder to enforce than the industry has assumed.
For companies that have built their exclusivity strategy around patent thickets—AbbVie settled with generic Rinvoq challengers to delay entry until 2037, using a strategy perfected with Humira—the Vascepa ruling is a reminder that patent strategy has limits. Settlements avoid the courtroom, but the SCOTUS decision suggests that if contested, some patent claims within those thickets might not hold. The ruling does not invalidate the settlement approach, but it narrows the enforceability of certain patent types and may embolden future generic challengers to litigate rather than settle.
The cardiovascular implications are also worth noting. Vascepa was the first FDA-approved therapy shown to reduce cardiovascular events in statin-treated patients with elevated triglycerides. Generic competition will lower prices and broaden access, but it also reduces the commercial incentive for Amarin and other companies to invest in similar cardiovascular risk-reduction programs. The tension between generic access (which benefits patients today) and branded exclusivity (which funds the R&D that benefits patients tomorrow) is a recurring theme in pharmaceutical policy. The SCOTUS ruling tips the balance marginally toward access at the expense of exclusivity.
Lilly Medicare Deal Restores Foundayo and Zepbound Coverage
What Happened: BioPharma Dive reported that Eli Lilly reached a Medicare agreement that includes coverage for Foundayo and restores coverage for Zepbound, “erasing what had been a commercial edge for rival Novo Nordisk.”
What This Means for the GLP-1 Competitive Landscape
The Medicare GLP-1 Bridge program launches July 1 at a $50 per month copay for eligible Medicare Part D beneficiaries. With the Lilly agreement now in place, the program will cover both Lilly products (Foundayo for oral convenience, Zepbound for injectable efficacy) alongside Novo’s products (oral Wegovy, injectable Wegovy).
The restoration of Zepbound coverage is particularly significant. BioPharma Dive’s characterization—”erasing what had been a commercial edge for rival Novo Nordisk”—captures the competitive dynamic precisely. Novo had secured Medicare coverage for oral Wegovy ahead of Lilly, giving it a first-mover advantage in the Medicare population. The Lilly deal eliminates that advantage.
For the approximately 65 million Medicare beneficiaries, the GLP-1 Bridge program represents the most significant expansion of obesity treatment access in the program’s history. Having both Lilly and Novo products available from day one—oral and injectable options from both companies—gives physicians and patients the full range of choices. The initial enrollment volume in the first weeks after July 1 will signal how quickly Medicare beneficiaries adopt GLP-1 therapy when cost barriers are reduced from hundreds of dollars per month to $50.
The competitive dynamics between Lilly and Novo in the Medicare population will play out over the remainder of 2026 and into 2027. Lilly’s three-tier obesity portfolio (Foundayo oral, Zepbound injectable, retatrutide maximum efficacy pending 2027 launch) gives it the broadest product range. Novo’s oral Wegovy generated $354 million in Q1 revenue and commanded nearly 65% of new obesity starts. The Medicare population adds a large new patient pool where both companies will compete for share.
Gilead Cuts 87% of Arcellx Workforce Post-Acquisition
What Happened: Gilead is laying off 192 of approximately 220 Arcellx employees following the close of its $7.8 billion acquisition, according to BioSpace WARN notices. The cuts include 108 at Arcellx’s Redwood City, California headquarters (effective June 30) and 84 in Rockville, Maryland (through April 2027).
What Integration Actually Looks Like
Arcellx’s lead program, anito-cel for multiple myeloma, is now fully within Gilead’s organization. The science transferred. The vast majority of the people who built the science did not.
An 87% workforce reduction is on the high end of pharma-biotech integrations, but the dynamic is not unusual. When a large pharmaceutical company acquires a clinical-stage biotech, the acquirer typically retains the lead program, the intellectual property, key data, and a small number of senior scientists or program leaders. The broader organization—corporate functions, early-stage research teams, operational staff, and often the management team that negotiated the deal—is absorbed into the acquirer’s existing infrastructure or eliminated entirely.
For Gilead, the Arcellx integration reflects a specific strategic calculus. Gilead already has a cell therapy organization built around Yescarta and its broader oncology infrastructure. Anito-cel slots into that existing framework. The operational functions that Arcellx maintained as an independent company—its own finance, legal, HR, clinical operations, manufacturing oversight—are redundant once the program moves into Gilead’s structure.
The execution risk is real. Anito-cel was built by the Arcellx team over years of development. Transferring a complex cell therapy program from the team that developed it to a new organization introduces continuity risk—institutional knowledge about manufacturing nuances, clinical trial management decisions, and regulatory interactions does not transfer automatically through documents and data packages. Cell therapy manufacturing in particular involves highly specialized processes where tacit knowledge (understanding why a specific parameter was set at a specific level, knowing which process steps are most sensitive to variation) can be as important as formal documentation.
Gilead is betting that its internal cell therapy capabilities, built through years of Yescarta commercial manufacturing and clinical operations, are sufficient to advance anito-cel without the team that created it. The bet is defensible—Gilead has more cell therapy operational experience than almost any other company. But the 87% workforce reduction means very few bridges between the old organization and the new one.
Strategic Themes
1. $106B Validates That 2026 Is a Structural M&A Cycle, Not a Temporary Spike
The CNBC figure confirms what the individual deal announcements have suggested all year: this is not a one-quarter burst of activity. It is a multi-quarter, multi-driver structural cycle driven by patent cliff urgency, China licensing productivity, biotech valuation attractiveness, and the convergence of multiple therapeutic breakthroughs (GLP-1 obesity, RAS oncology, ADC combinations, in vivo CAR-T) that create acquisition targets across the modality spectrum. The 44% increase in average deal value ($527 million versus $365 million) shows that companies are acquiring later-stage, higher-quality assets—not speculating on early-stage science.
2. The Vascepa Ruling Narrows Patent Enforcement and Could Embolden Generic Challengers
Method-of-treatment patents just got harder to defend at the highest level of the U.S. judicial system. For companies whose exclusivity strategies depend on patent thickets that include method-of-treatment claims alongside composition-of-matter patents, the ruling introduces uncertainty. It does not invalidate the patent settlement approach that AbbVie and others have used successfully, but it provides a legal precedent that future generic challengers can cite when deciding whether to litigate rather than settle. The long-term effect may be a shift toward more aggressive generic challenges and shorter effective exclusivity periods for branded drugs.
3. The Medicare GLP-1 Playing Field Is Now Level—and July 1 Will Test Demand
With both Lilly (Foundayo, Zepbound) and Novo (oral Wegovy, injectable Wegovy) covered under the Bridge program at $50 per month, the competitive dynamics shift to product differentiation rather than coverage availability. The initial enrollment data after July 1 will provide the first real-world signal of GLP-1 demand in the Medicare population—a dataset that analysts, investors, and policymakers will scrutinize closely to assess whether the Bridge program structure achieves its goal of expanding access while managing costs.
4. Gilead’s 87% Workforce Cut Shows the Human Cost of Pharma M&A Integration
The numbers are stark: 192 of 220 employees. $7.8 billion in acquisition value. The premium went to shareholders. The jobs went away. This is the operational reality of large pharma acquiring small biotech, and it is repeated across the industry in every acquisition cycle. The strategic logic is sound (Gilead gets anito-cel for its myeloma pipeline), but the human impact is a reminder that M&A statistics represent real people and real careers, not just deal values and milestone payments.
Frequently Asked Questions
How much biotech M&A has occurred in 2026?
$106 billion through early June across 201 deals, according to CNBC citing PitchBook data. Average deal value $527 million, up 44% from $365 million in 2025. On pace for the best M&A year since before COVID.
What did CNBC say about China deals?
AstraZeneca, Pfizer, and Bristol Myers Squibb have each allocated more than $16 billion to collaborations with Chinese drugmakers since the start of 2025. Forbion’s Luneborg said “clearly the interest in buying assets out of China is not fading” despite regulatory uncertainty.
What is the Vascepa ruling?
The U.S. Supreme Court ruled that Hikma’s generic version of Amarin’s Vascepa does not infringe Amarin’s method-of-treatment patents. The ruling narrows the enforceability of this patent type and could embolden future generic challengers.
What is the Lilly Medicare deal?
Lilly reached an agreement that includes coverage for both Foundayo and Zepbound under the Medicare GLP-1 Bridge program launching July 1 at $50 per month copay. BioPharma Dive said it “erases” what had been a commercial advantage for Novo Nordisk.
What happened at Arcellx?
Gilead is laying off 192 of approximately 220 employees (87%) following its $7.8 billion acquisition. The anito-cel program for multiple myeloma transfers to Gilead’s organization. Cuts affect Redwood City headquarters (108 employees, effective June 30) and Rockville operations (84 employees, through April 2027).
When is the Medicare GLP-1 Bridge launching?
July 1, 2026. Both Lilly (Foundayo, Zepbound) and Novo (oral Wegovy, injectable Wegovy) products are now covered at $50 per month copay.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
$106B and Counting. We analyze why CNBC’s M&A figure validates the structural thesis we have tracked since Q1, assess the full-year pace and what it implies for H2 deal volume, and evaluate whether the $527M average deal value signals a shift toward higher-quality, later-stage acquisitions.
Vascepa SCOTUS Ruling. We assess what the patent decision means for method-of-treatment patent enforceability across pharma, how it interacts with the AbbVie patent settlement playbook (Humira, Rinvoq), and whether the ruling could encourage more generic challengers to litigate rather than settle.
Gilead/Arcellx Integration. We analyze what the 87% workforce reduction tells you about pharma-biotech integration dynamics, assess the execution risk of advancing anito-cel without the original development team, and compare the Arcellx cuts to historical integration benchmarks.
Plus: Lilly Medicare competitive positioning, GLP-1 Bridge launch readiness, Revolution filing status, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
